FDA requires eye‑risk warning on all GLP‑1 drugs

The U.S. Food and Drug Administration issued a safety communication on Nov. 9 requiring manufacturers of GLP‑1 receptor agonists to add a warning about non‑arteritic anterior ischemic optic neuropathy (NAION). The agency cited studies showing an incidence of 6.4 cases per 100,000 person‑years among GLP‑1 users versus 3.8 in placebo or other glucose‑lowering drug users. The warning applies to Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound, and comes as nearly 280 related lawsuits have been consolidated in federal court.

The labeling change may increase prescribing caution and could affect sales of the affected brands, while also influencing litigation risk for Novo Nordisk and Eli Lilly (the companies note the risk remains low and benefits may outweigh it).

  • 1The FDA announced the labeling requirement on Nov. 9, 2026.
  • 2The warning covers all GLP‑1 receptor agonists, including Ozempic, Wegovy, Mounjaro and Zepbound.
  • 3Researchers identified an incidence of 6.4 cases of NAION per 100,000 person‑years among GLP‑1 users.
  • 4The incidence among placebo or other glucose‑lowering medication users was 3.8 cases per 100,000 person‑years.
  • 5Nearly 280 GLP‑1‑related NAION lawsuits have been consolidated in a Philadelphia federal court.

Sources